Sorafenib therapy for BCLC stage B/C hepatocellular carcinoma; clinical outcome and safety in aged patients: A multicenter study in Japan

Journal of Cancer

Volumn 5, Issue 7, 2014, Pages 499-509

  Nishikawa, Hiroki ^a   Takeda, Haruhiko ^a   Tsuchiya, Kaoru ^b   Joko, Kouji ^c   Ogawa, Chikara ^d   Taniguchi, Hiroyoshi ^e   Orito, Etsuro ^f   Uchida, Yasushi ^g   Osaki, Yukio ^a   Izumi, Namiki ^b  

^a OSAKA RED CROSS HOSPITAL   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

^c MATSUYAMA RED CROSS HOSPITAL   (Japan)

^d TAKAMATSU RED CROSS HOSPITAL   (Japan)

^e JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^f NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^g MATSUE RED CROSS HOSPITAL   (Japan)

Author keywords

Aged patients; Clinical outcome; Hepatocellular carcinoma; Safety; Sorafenib

Indexed keywords

SORAFENIB;

ABLATION THERAPY; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; JAPAN; LIVER ANGIOGRAPHY; LIVER CELL CARCINOMA; LIVER INJURY; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERCUTANEOUS BIOPSY; PERCUTANEOUS ETHANOL INJECTION; PORTAL PHLEBOGRAPHY; PROGRESSION FREE SURVIVAL; PROPENSITY SCORE; RADIOFREQUENCY ABLATION; RECOMMENDED DRUG DOSE; SELECTION BIAS; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

EID: 84902954315     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.9257     Document Type: Article

References (48)

1. Kudo M: Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 2010; 78: 113-124.
2. Livraghi T, Mäkisalo H, Line PD: Treatment options in hepatocellular carcinoma today. Scand J Surg 2011; 100: 22-29.
3. de Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol 2012; 56 Suppl 1: S75-S87.
4. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.
5. Hankey BF, Ries LA, Kosary CL, et al: Partitioning linear trends in age-adjusted rates. Cancer Causes Control 2000; 11: 31-35.
6. Cho SJ, Yoon JH, Hwang SS, Lee HS: Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol 2007; 22: 1226-1231.
7. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
8. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:4293-4300.
9. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
10. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet 1990; 335(8696): 1020-2.
11. Takahashi H, Mizuta T, Kawazoe S, et al: Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients. Hepatol Res 2010; 40:997-1005.
12. Bove A, Bongarzoni G, Di Renzo RM, Marsili L, Chiarini S, Corbellini L:Efficacy and safety of ablative techniques in elderly HCC patients. Ann Ital Chir 2011; 82: 457-463.
13. Massarweh NN, Park JO, Yeung RS, Flum DR: Comparative assessment of the safety and effectiveness of radiofrequency ablation among elderly medicare beneficiaries with hepatocellular carcinoma. Ann Surg Oncol 2012; 19:1058-1065.
14. Hiraoka A, Michitaka K, Horiike N, et al: Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J Gastroenterol Hepatol 2010; 25:403-407.
15. Kondo K, Chijiiwa K, Funagayama M, Kai M, Otani K, Ohuchida J: Hepatic resection is justified for elderly patients with hepatocellular carcinoma. World J Surg 2008; 32: 2223-2229.
16. Oishi K, Itamoto T, Kobayashi T, et al: Hepatectomy for hepatocellular carcinoma in elderly patients aged 75 years or more. J Gastrointest Surg 2009; 13:695-701.
17. Huang J, Li BK, Chen GH, et al: Long-term outcomes and prognostic factors of elderly patients with hepatocellular carcinoma undergoing hepatectomy. J Gastrointest Surg 2009; 13: 1627-1635.
18. Yau T, Yao TJ, Chan P, et al: The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization. Cancer 2009; 115: 5507-5515.
19. Mirici-Cappa F, Gramenzi A, Santi V, et al: Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut 2010; 59: 387-396.
20. Yanaga K, Kanematsu T, Takenaka K, Matsumata T, Yoshida Y, Sugimachi K:Hepatic resection for hepatocellular carcinoma in elderly patients. Am J Surg 1988; 155: 238-241.
21. Fortner JG, Lincer RM: Hepatic resection in the elderly. Ann Surg 1990; 211:141-145
22. Yamamoto K, Takenaka K, Matsumata T, et al: Right hepatic lobectomy in elderly patients with hepatocellular carcinoma. Hepatogastroenterology 1997; 44:514-518.
23. Ezaki T, Yukaya H, Ogawa Y: Evaluation of hepatic resection for hepatocellular carcinoma in the elderly. Br J Surg 1987; 74: 471-473.
24. Nagasue N, Chang YC, Takemoto Y, Taniura H, Kohno H, Nakamura T: Liver resection in the aged (seventy years or older) with hepatocellular carcinoma. Surgery 1993; 113: 148-154.
25. Takenaka K, Shimada M, Higashi H, et al: Liver resection for hepatocellular carcinoma in the elderly. Arch Surg 1994; 129: 846-850.
26. Miyagawa S, Makuuchi M, Kawasaki S, Kakazu T: Criteria for safe hepatic resection. Am J Surg 1995; 169: 589-594.
27. Nishikawa H, Osaki Y, Iguchi E, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: clinical outcome and safety in elderly patients. J Gastrointestin Liver Dis 2012; 21(4): 397-405.
28. Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Surgical resection for hepatocellular carcinoma: clinical outcomes and safety in elderly patients. Eur J Gastroenterol Hepatol 2013; 25(8): 912-9.
29. Wong H, Tang YF, Yao TJ, et al. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist 2011; 16(12): 1721-8.
30. Di Costanzo GG, Tortora R, De Luca M, et al. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med Oncol 2013; 30(1): 446.
31. Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review. J Cancer 2013; 4(8): 635-643.
32. Morimoto M, Numata K, Kondo M, et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res 2011; 41(4): 296-302.
33. Kudo M, Izumi N, Kokudo N, et al; HCC Expert Panel of Japan Society of Hepatology: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29:339-364.
34. Miller AA, Murry DJ, Owzar K, et al. Phase I and Pharmacokinetic Study of Sorafenib in Patients with Hepatic or Renal Dysfunction. J Clin Oncol 2009; 27:1800-5.
35. McCurry J. Japan battles with obesity. Lancet 2007; 369: 451-52.
36. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J 2002; 66: 987-992.
37. Shiwaku K, Anuurad E, Enkhmaa B, Kitajima K, Yamane Y. Appropriate BMI for Asian populations. Lancet 2004; 363: 1077.
38. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30(1): 52-60.
39. D'Agostino RB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281, 1998.
40. Jo M, Yasui K, Kirishima T, et al. Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatol Res. 2014; [Epub ahead of print].
41. Iavarone M, Cabibbo G, Piscaglia F, et al; SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54(6):2055-63.
42. Pili R, Guo Y, Chang J, Nakanishi H, Martin GR, Passaniti A. Altered angiogenesis under lying age-dependent changes in tumor growth. J Natl Cancer Inst 1994; 86: 1303-14.
43. Yao D, Jiang D, Huang Z, et al. Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000; 88(4): 761-9.
44. Zhang JB, Chen Y, Zhang B, et al. Prognostic significance of serum gamma- glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol 2011; 23(9): 787-93.
45. Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer. 2013; 2:93-107.
46. Sampat KR, O'Neil B. Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist. 2013; 18(4): 430-8.
47. Scartozzi M, Faloppi L, Svegliati Baroni G, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study. Int J Cancer. 2014; [Epub ahead of print].
48. Lee JH, Chung YH, Kim JA, et al. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer. 2013; 119(1): 136-42.